John and others:
You are all welcome.
I am well aware of QLTI (as well as PCYC and MRVT) work with photo-chemicals as drug-therapy for cancers and AMD. Also, QLTI stock price rise ~300% (in last few months) after positive AMD PIII data.
Regards the PKC 412, it is Novartis oral experimental drug (CGP 41251), currently in initial PI cancer trials. Probably CIBA Vision will explore further 41251-derivative for MD.
So, what this have to do with SUGN????
To be successful bt sector investor, one have to constantly look ahead few steps with wide angle. To *jump in* or *bail out* before the next guy.
Regards the SUGN, at this point, I do not see even slight sign for *bail out*. However there are still signs to *jump in*. On sign is this discussion on anti-angiogenesis approach for MD therapy. Novartis preclinical results with 41251 (however, dose of 300-600 mg/kg in MD model are several fold higher than regular dose, 10-20 mg/kg, which were acceptable as safety range in animal cancer model) indicate that TKs target is good one. Also, NXTR have VEGF-aptamer in AMD PI trial and AGPH have MMPs inhibitor AG3340 in PII MD trial.
In my last conversation with SUGN IR (Mrs. K. Susan) I asked did Allergan-SUGN selected lead anti-angio compound for MD. The answer was NO! I guess here that SUGN can't license to AGN SU xxxx class compounds (indolinone derivatives) because it will be conflict of interest/drug indications. However, I do not know does SUGN have any restriction on their cancer candidates in regards the other indications (and in connection with ALG collaboration), like AMD. They are free to explore candidates for inflammatory indications.
ALL IN ALL, I do not see any reason why SUGN will not explore SU6668 (if safety results are positive) for MD.
Miljenko
|
